| 68Ga PSMA in Preprostatectomy Patients (NCT03388346) | Michael Graham PhD, MD | 2018-02-16 |
| Correlation Between iXip and Final Pathology Specimen From Radical Prostatectomy: a Multicenter Prospective Trial (NCT03413007) | Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia | 2018-02-09 |
| Gallium-68 PSMA-11 PET in Patients With Biochemical Recurrence (NCT03396874) | University of Michigan | 2018-02-09 |
| Nivolumab and Ipilimumab Treatment in Prostate Cancer With an Immunogenic Signature (NCT03061539) | University College, London | 2018-02-06 |
| Randomized Trial of eOncoNote (NCT03333785) | University of Toronto | 2018-02-05 |
| Upregulation of PSMA Receptors After Androgen Deprivation Therapy on PSMA PET/CT Imaging in Prostate Cancer (NCT03938766) | Jewish General Hospital | 2018-02-02 |
| 18F-fluorocholine and 18F-fluoride PET in Prostate Cancer (NCT04340765) | Buddhist Tzu Chi General Hospital | 2018-02-01 |
| The Accuracy of Modified TTMB in the Spatial Distribution of Prostate Cancer (NCT03418207) | Subei People's Hospital of Jiangsu Province | 2018-02-01 |
| Using Decision Analysis to Enhance Decision-Making Regarding Prostate Cancer Screening (NCT03387527) | Case Comprehensive Cancer Center | 2018-02-01 |
| PD-L1 Inhibition as ChecKpoint Immunotherapy for NeuroEndocrine Phenotype Prostate Cancer (NCT03179410) | Andrew J. Armstrong, MD | 2018-02-01 |
| Multi-Targeted Recombinant Ad5 (CEA/MUC1/Brachyury) Based Immunotherapy Vaccine Regimen in People With Advanced Cancer (NCT03384316) | National Cancer Institute (NCI) | 2018-01-31 |
| Race-related Alternative Splicing: Novel Targets in Prostate Cancer (NCT03424213) | Duke University | 2018-01-30 |
| Kinetics of Perioperative Circulating DNA in Cancer Surgery (NCT03284684) | Centre Hospitalier Universitaire de Nīmes | 2018-01-22 |
| Pilot Cohort Study of Rb-82 Myocardial PET Imaging to Evaluate Coronary Microvascular Dysfunction in Men With Prostate Cancer Receiving Androgen-Deprivation Therapy (NCT03535987) | Abramson Cancer Center at Penn Medicine | 2018-01-19 |
| A Study of Grape Seed Extract in Asymptomatic Non-Metastatic Prostate Cancer Patients With Rising PSA (NCT03087903) | University of Colorado, Denver | 2018-01-18 |
| Highly Conformal, Hypofractionated, Focally Dose Escalated Post-Prostatectomy Radiotherapy (NCT03388619) | National Cancer Institute (NCI) | 2018-01-17 |
| Assessing Circulating Tumor Cell as a Biomarker for Prostate Cancer Detection in Patients With Gray Zone PSA Level (NCT03488706) | CellMaxLife | 2018-01-17 |
| Pilot Trial of Chemohormonal Therapy Followed by Prostatectomy in High Risk Prostate Cancer (NCT03358563) | University of Wisconsin, Madison | 2018-01-17 |
| Head- to Head Comparison of [68Ga]Ga-PSMA-11 With [18F]PSMA-1007 PET/CT in Staging Prostate Cancer Using Histopathology and Immunohistochemical Analysis as Reference-Standard (NCT04159090) | Tel-Aviv Sourasky Medical Center | 2018-01-15 |
| Evaluation of a Blood Biomarker to Try and Distinguish Between the Presence or Absence of Aggressive Prostate Cancer (NCT03256630) | Genomic Health®, Inc. | 2018-01-10 |
| PSMA-PET/CT for Prostate Cancer (NCT03558711) | University Hospital, Ghent | 2018-01-04 |
| Isatuximab in Combination With REGN2810 (Cemiplimab) in Patients With Advanced Malignancies (NCT03367819) | Sanofi | 2018-01-04 |
| BioProtect Balloon Implant™ Balloon System Pivotal Study BP-007 (NCT03400150) | BioProtect | 2018-01-03 |
| Ablative Therapy in the Management of Prostate Cancer (NCT03492424) | Weill Medical College of Cornell University | 2018-01-02 |
| Place of 68Ga-PSMA-11 PET-CT in the Therapeutic Decision at the End of the Initial Staging for High Risk Prostate Cancer Patients (NCT03344822) | Central Hospital, Nancy, France | 2018-01-02 |
| A Tailored Polygenic Risk Score for Predicting Progression in Prostate Cancer Under Active Surveillance (NCT07491406) | IRCCS San Raffaele | 2018-01-01 |
| Prognostic Value of SPECT-CT Quantitative Indices for the Response Assessment of Bone Metastatic Prostate Carcinoma (NCT03382522) | University Hospital, Brest | 2018-01-01 |
| The Relationship Between Serum PSA Levels and WBC, Delta Neutrophil Index (DNI) and Other Hematological Parameters (NCT05399940) | Hisar Intercontinental Hospital | 2018-01-01 |
| Improving Prostate Lesion Classification and Development of a PI-RADS 3 Classifier (NCT06116344) | Paracelsus Medical University | 2018-01-01 |
| Capture of Prostatic Trans-rectal Ultrasound Scans for Research (NCT03321864) | Cambridge University Hospitals NHS Foundation Trust | 2018-01-01 |
| Tumor Molecular Profiling in Patients With Prostate Cancer (NCT05573789) | Hellenic Cooperative Oncology Group | 2018-01-01 |
| Early and Accurate Detection of Prostate Cancer in General Practice (NCT03431753) | Aarhus University Hospital | 2018-01-01 |
| Evaluating an Alternative Clinical Genetics Cancer Care Deliver Model (NCT03934606) | Abramson Cancer Center at Penn Medicine | 2018-01-01 |
| Innovations in the Treatment of Sexual Health Post Prostate Cancer Treatment: Comparing Mindfulness vs. CBT (NCT03365518) | University of British Columbia | 2017-12-29 |
| A Prospective, Randomized Trial Comparing Office-based MR-guided Prostate Biopsy Approaches (NCT03632655) | Weill Medical College of Cornell University | 2017-12-23 |
| Clinical Trial of Metastasis Inhibitor NP-G2-044 in Patients With Advanced or Metastatic Treatment-Refractory Solid Tumor Malignancies (NCT03199586) | Novita Pharmaceuticals, Inc. | 2017-12-21 |
| An Investigational Immunotherapy Study of Nivolumab in Combination With Rucaparib, Docetaxel, or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (NCT03338790) | Bristol-Myers Squibb | 2017-12-19 |
| Valid Biomarkers in Blood to Predict the Response to Therapy in Prostate Cancer Patients (NCT03408964) | Oncology Institute of Southern Switzerland | 2017-12-15 |
| Exercise Intervention Among Men With Prostate Cancer Initiating Androgen Deprivation Therapy (NCT03070145) | Dana-Farber Cancer Institute | 2017-12-08 |
| Prognostic Value of Androgen Receptor Expression and Mutations Within Oncogenes and Tumor Suppressor Genes in Patients Treated for High Risk Prostate Cancer With Proton Therapy (PRX32) (NCT03296124) | University of Florida | 2017-12-07 |
| High Resolution PET-MRI Before Prostate Cancer HIFU (NCT03263780) | Timothy J. Daskivich | 2017-12-07 |
| Prostate Cancer Detection Rates of Standard Transrectal Prostate Biopsy and MR-guided Fusion Transrectal Prostate Biopsy (NCT03936296) | TC Erciyes University | 2017-12-06 |
| ODM-201 vs Androgen Deprivation Therapy in Hormone naïve Prostate Cancer (NCT02972060) | European Organisation for Research and Treatment of Cancer - EORTC | 2017-12-01 |
| Luteinizing Hormone-releasing Hormone Analogue and Enzalutamide +/- Zoledronic Acid in Prostate Cancer Patients (NCT03336983) | Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia | 2017-12-01 |
| Early DVC Ligation and Urinary Continence Recovery After RARP (NCT03368378) | IRCCS San Raffaele | 2017-11-28 |
| Randomized Phase II Study of Salvage XRT + ADT +/- Abiraterone and Apalutamide for Rising PSA After RP (FORMULA-509) (NCT03141671) | Dana-Farber Cancer Institute | 2017-11-24 |
| CABAzitaxel With or Without Prednisone in Patients With Metastatic CAstration REsistant Prostate Cancer Progressed During or After a Previous Docetaxel-based Chemotherapy (NCT03356912) | Consorzio Oncotech | 2017-11-22 |
| Genetic Counseling Processes and Outcomes Among Males With Prostate Cancer (ProGen) (NCT03328091) | Dana-Farber Cancer Institute | 2017-11-21 |
| NBTXR3 Nanoparticles and EBRT or EBRT With Brachytherapy in the Treatment of Prostate Adenocarcinoma (NCT02805894) | Nanobiotix | 2017-11-15 |
| Study to Evaluate the Safety and Efficacy of Switching From Zoladex® Monthly or Quarterly, to Eligard® Semiannual. (NCT05304169) | Zodiac Produtos Farmaceuticos S.A. | 2017-11-14 |
| US-CT Fusion for Post Implant Dosimetry (NCT03692104) | British Columbia Cancer Agency | 2017-11-03 |
| Weight Management Aimed to Reduce Risk and Improve Outcomes From Radical Prostatectomy (NCT03261271) | University of Kansas Medical Center | 2017-11-02 |
| MRI in PROstate Cancer Diagnosis With Prior Risk Assessment (NCT03225222) | Erasmus Medical Center | 2017-11-01 |
| Docetaxel Versus Abiraterone as First-line Treatment in mCRPC Patients With Intraductal Carcinoma of the Prostate (NCT03356444) | West China Hospital | 2017-11-01 |
| SAKK 08/15 - PROMET - Salvage Radiotherapy +/- Metformin for Patients With Prostate Cancer After Prostatectomy (NCT02945813) | Swiss Cancer Institute | 2017-10-24 |
| Preference-Based Exercise RCT for Men With PC on ADT (NCT03335631) | University Health Network, Toronto | 2017-10-19 |
| Reconstitution of a Human Immune System in a Patient Derived Xenograft (PDX) Model of Genitourinary (GU) Cancers (NCT03134027) | Duke University | 2017-10-19 |
| The Impact of Low Pressure Pneumo in RARP (NCT03370016) | Metro Health, Michigan | 2017-10-17 |
| Genistein Supplementation to Mitigate Cardiometabolic Dysfunction in Patients Undergoing Androgen Deprivation Therapy for Prostate Cancer (NCT02766478) | Emory University | 2017-10-16 |
| Fusion Guided Focal Laser Ablation of Prostate Cancer (NCT02759744) | National Institutes of Health Clinical Center (CC) | 2017-10-13 |
| Study of Abiraterone Acetate Plus ADT Versus APALUTAMIDE Versus Abiraterone and APALUTAMIDE in Patients With Advanced Prostate Cancer With Non-castrate Testosterone Levels (NCT02867020) | Latin American Cooperative Oncology Group | 2017-10-11 |
| Predictive and Prognostic Markers for Treatment Outcomes in Prostate Cancer Patients (NCT03237026) | National Taiwan University Hospital | 2017-10-11 |
| AZD5363 in Patients With Advanced Solid Tumors Harboring AKT Mutations (NCT03310541) | Memorial Sloan Kettering Cancer Center | 2017-10-11 |
| Phase I Trial of 225Ac-J591 in Patients With mCRPC (NCT03276572) | Weill Medical College of Cornell University | 2017-10-10 |
| Multi-parametric Magnetic Resonance Imaging for Prostate Cancer Patients (NCT03180398) | Henry Ford Health System | 2017-10-04 |
| 4Kscore Using Serum Stored Uncentrifuged (NCT04130776) | OPKO Health, Inc. | 2017-10-04 |
| Evaluation of a Postural Rehabilitation Program Based on Sensory-motor Control in Men With Urinary Incontinence After Prostatectomy (NCT03027986) | University Hospital, Rouen | 2017-10-02 |
| PSMA-PET Imaging in Patients With Metastatic Prostate Cancer: Institutional Evaluation of Detection Yield Performance and Reproducibility (NCT03486886) | Centre hospitalier de l'Université de Montréal (CHUM) | 2017-10-02 |
| Prospective Evaluation of Mp-MRI, MR-guided Biopsy, and Molecular Markers for Active Surveillance of Prostate Cancer (NCT03979573) | Heinrich-Heine University, Duesseldorf | 2017-10-01 |
| Investigating Bone and Skeletal Muscle Interaction in Men With Prostate Cancer (NCT03386812) | University of Texas Southwestern Medical Center | 2017-10-01 |
| Focal Prostate Ablation Versus Radical Prostatectomy (NCT03668652) | Oslo University Hospital | 2017-09-30 |
| Low Dose Hemi-body Radiation For Recurrent Prostate Cancer (NCT03196778) | Juravinski Cancer Center | 2017-09-25 |
| High Precision Imaging of Prostate Specific Membrane Antigen for Personalized Treatment in Prostate Cancer (NCT03327675) | Universitaire Ziekenhuizen KU Leuven | 2017-09-22 |
| The Effect of ADT on PSMA-PET. (NCT03313726) | Turku University Hospital | 2017-09-20 |
| Gallium-68 PSMA-11 Positron Emission Tomography (PET) Imaging in Patients With Biochemical Recurrence (NCT03353740) | Thomas Hope | 2017-09-20 |
| Prostate Health Index for Prostate Cancer Diagnosis (NCT03151356) | Hospices Civils de Lyon | 2017-09-18 |
| Evaluation of Oncoxin-Viusid® in Prostate Cancer (NCT03543670) | Catalysis SL | 2017-09-16 |
| Long-term Study to Evaluate and Clinical Outcomes in Patients With Favorable Intermediate Risk Localized Prostate Cancer (NCT03290508) | Myriad Genetic Laboratories, Inc. | 2017-09-14 |
| Investigating and Characterizing the Immune Response to Prostate Cancer (NCT03331367) | NYU Langone Health | 2017-09-14 |
| Hemi-Gland Cryoablation for Prostate Cancer at UCLA (NCT03503643) | Jonsson Comprehensive Cancer Center | 2017-09-14 |
| Smart After-Care in Patients With Prostate Cancer (NCT03264209) | Ji Youl Lee | 2017-09-11 |
| Survivorship Care Plans in a Community Oncology Practice (NCT03028584) | University of Wisconsin, Madison | 2017-09-11 |
| Multiparametric Ultrasound Imaging in Prostate Cancer (NCT03101176) | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | 2017-09-07 |
| Correlative Analysis of the Genomics of Vitamin D and Omega-3 Fatty Acid Intake in Prostate Cancer (NCT03290417) | Case Comprehensive Cancer Center | 2017-09-07 |
| Effect of Anesthesia on Optic Nerve Sheath Diameter in Patients Undergoing Robot-assisted Laparoscopic Prostatectomy (NCT03271502) | Asan Medical Center | 2017-09-04 |
| From PSA to Stockholm3: Study Part 1 (NCT03381105) | Helse Stavanger HF | 2017-09-01 |
| INTERVAL - Intense Exercise Trial for Men With Metastatic Castrate-Resistant Prostate Cancer (NCT04507698) | Guy's and St Thomas' NHS Foundation Trust | 2017-09-01 |
| Effect of Ruxolitinib on Tumor Infiltrating Myeloid Cells (NCT03274778) | Oncology Institute of Southern Switzerland | 2017-09-01 |
| ONE-SHOT Trial - Ultra-hypofractionated Single-dose SBRT for Prostate Cancer (NCT03294889) | University Hospital, Geneva | 2017-09-01 |
| Prostate Nutrition and Exercise STudy (ProNEST) (NCT03173807) | University of Pittsburgh | 2017-08-31 |
| Radiotherapy to the Prostate and Dominant Intra-Prostatic Lesion (DIL) (NCT03269422) | Memorial Sloan Kettering Cancer Center | 2017-08-28 |
| Tisotumab Vedotin Continued Treatment in Patients With Solid Tumors. (NCT03245736) | Seagen Inc. | 2017-08-23 |
| A Study of IMP4297 in Patients With Advanced Solid Tumors (NCT03508011) | Impact Therapeutics, Inc. | 2017-08-23 |
| Sexual Health and Rehabilitation eClinic (SHAReClinic) (NCT03396848) | University Health Network, Toronto | 2017-08-23 |
| A Trial of Androgen Deprivation, Docetaxel, and Enzalutamide for Metastatic Prostate Cancer (NCT03246347) | Wake Forest University Health Sciences | 2017-08-23 |
| Stereotactic Body Radiation Therapy for Spinal Metastases in Favorite Tumors (NCT03392233) | RenJi Hospital | 2017-08-18 |
| Ex-vivo Investigation of Beta Probe for Prostate Cancer Resection and Evaluation of PSMA-PET for Diagnosis of Intraprostatic Lesions (NCT03213951) | Indiana University | 2017-08-18 |
| Effects of High-intensity Training Compared to Resistance Training in Cancer Patients Undergoing Radiotherapy (NCT03252821) | Cliniques universitaires Saint-Luc- Université Catholique de Louvain | 2017-08-15 |
| Evaluation of the Predictive Role of Choline PET/CT on the Survival of Patients Affected by Prostate Cancer. (NCT06158178) | IRCCS San Raffaele | 2017-08-08 |
| 18F-DCFPyL PET/CT in High Risk and Recurrent Prostate Cancer (NCT03181867) | National Cancer Institute (NCI) | 2017-08-03 |